Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Clinical Trial

Official title:

A Multicenter, Open-label, Phase IIb Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05168566
• Other study ID #: SZCT-2020-06
• Status: Recruiting
• Phase: Phase 2
• Start date: September 1, 2022
• Est. completion date: February 2025

Study information

• Verified date: May 2023
• Source: Teligene US
• Contact: Xiaoyang Xia
• Phone: 805-300-9373
• Email: Xiaoyang.xia[@]teligene.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)

Description:

Sutetinib is an investigational irreversible EGFR tyrosine kinase inhibitor. EGFR is a gene that makes a protein that is involved in cell growth and cell survival. Mutated (changed) forms of the EGFR gene and protein have been found in some types of cancer, including non-small cell lung cancer. These changes may cause cancer cells to grow and spread in the body. The purpose of this study is to explore how effective Sutetinib maleate capsules are for the treatment of patients with locally advanced or metastatic NSCLC with non-resistant uncommon EGFR mutations

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 99
• Est. completion date: February 2025
• Est. primary completion date: August 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age 18 years old and above, male or female.

2. Histopathological and/or cytopathological confirmation of locally advanced or metastatic NSCLC patients with = 1 prior line of chemotherapy.

3. Confirmation that the tumor harbors a non-resistant uncommon EGFR mutation (tumor tissue biopsy), including one or more of L861Q, G719X and S768I mutations, excluding any other EGFR sensitive mutations and/or oncogenes..

4. At least one measurable lesion.

5. ECOG score of 0, 1, or 2.

6. A minimum life expectancy of > 3 months.

7. Adequate bone marrow reserve, hepatic, renal and coagulation function.

8. Willingness of all subjects of childbearing potential to use acceptable methods of birth control.

Exclusion Criteria:

1. Ever used the epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) for anti-tumor therapy prior to enrollment.

2. Any systemic anti-tumor therapy such as chemotherapy, immunotherapy and radiation therapy used within 4 weeks prior to enrollment; any palliative radiotherapy for non-target lesions used to relieve symptoms and traditional Chinese medicines indicated for tumor within 2 weeks prior to enrollment.

3. Use or intake of drugs or foods containing potent inhibitor or inducer of cytochrome P450 isozyme 3A4 (CYP3A4) within 14 days or 5 half-lives, whichever was the longer, prior to enrollment.

4. Surgical operation (excluding aspiration biopsy) of main organs or a significant injury within 4 weeks prior to enrollment.

5. Any unresolved toxicities from prior therapy greater than Grade 1 at the time of screening except alopecia.

6. Inability to swallow the study medication, any seriously chronic gastrointestinal disorder, malabsorption syndrome or any other conditions with influence on gastrointestinal absorption.

7. Active central nervous system metastases

8. Previous or current interstitial lung disease, radiation pneumonitis which requires hormone therapy, or drug-related pneumonia, idiopathic interstitial pulmonary fibrosis identified in a baseline CT scan; uncontrolled massive pleural or pericardial effusion.

9. Any active infection which has not been controlled at screening.

10. Any serious cardiovascular disease.

11. History of other serious systemic disease not suitable for clinical trial.

12. Participation in other interventional clinical trial 4 weeks prior to enrollment or within 5 half-lives from the last dose of investigational product (whichever is longer).

13. Known alcohol or drug dependence.

14. Mental disorders or poor compliance.

15. Previously received solid organ transplantation or hematopoietic stem cell transplantation.

16. Females who are pregnant or breastfeeding.

17. Known hypersensitivity to the active ingredients or excipients of the investigational product.

18. Have any other primary malignant tumors within 3 years (except some low- risk cancers).

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-small Cell Lung Cancer

Intervention

Drug:
• Sutetinib Maleate Capsule
Study drug to be taken orally with or without food (with food preferred) for up to13 cycles

Locations

Country	Name	City	State
United States	University of Maryland Medical Center	Baltimore	Maryland
United States	OPN Healthcare, Inc.	Glendale	California
United States	The University of Texas- MD Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Teligene US

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessment of Objective response rate (ORR)	Objective response rate (ORR) assessed by IRC	2 Years
Secondary	Assessment of Duration of response (DoR)		2 Years
Secondary	Assessment of Disease control rate (DCR)		2 Years
Secondary	Assessment of Progression free survival (PFS)		2 Years
Secondary	Assessment of Time to progressive disease		2 Years
Secondary	Assessment of Time to response		2 Years
Secondary	Assessment of Time to treatment failure (TTF)		2 Years
Secondary	Assessment of Overall survival (OS)		2 Years
Secondary	Assessment of 1-year progression-free survival		1 Year
Secondary	Assessment of 1-year survival		1 Years
Secondary	Assess incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]).	Safety and tolerability as determined by the incidence of adverse events (AEs), including severe AEs and serious AEs(SAEs)	2 Years
Secondary	Assessment of Peak Plasma Concentration (Cmax) or Area under the plasma concentration versus time curve (AUC)		2 Years